Literature DB >> 1658013

Platelet factor 4 selectively inhibits binding of TGF-beta 1 to the type I TGF-beta 1 receptor.

R H Whitson1, W L Wong, K Itakura.   

Abstract

A low molecular weight inhibitor of TGF-beta 1 binding was detected in partially purified human platelet extracts by using Hep 3B hepatoma cells in the binding assays. The inhibitory protein was purified to homogeneity and was identified as platelet factor 4 on the basis of its amino acid sequence. TGF-beta 1 binding to Hep 3B cells was almost completely inhibited by 100 nM concentrations of platelet factor 4, but TGF-beta 1 binding to NRK 49F fibroblasts was inhibited only slightly. Affinity cross-linking experiments revealed that these differences in the inhibition of TGF-beta 1 binding by platelet factor 4 were due to differences in the complements of TGF-beta 1 binding proteins present on these two cell types. In Hep 3B cells the majority of bound TGF-beta 1 was cross-linked to a complex which had an apparent molecular weight of 70 kDa. TGF-beta 1 binding to this protein was the most sensitive to inhibition by platelet factor 4. Based on its size and TGF-beta 1 binding properties, we believe this protein is the type I TGF-beta 1 receptor. Hep 3B cells also had a high-affinity TGF-beta 1 binding protein which appeared as an 80 kDa complex, and which we believe to be the type II TGF-beta 1 receptor. TGF-beta 1 binding to this protein was not inhibited by platelet factor 4. TGF-beta 1 was also cross-linked to complexes of higher molecular weights in Hep 3B cells, but it was not clear whether any of them represented the type III TGF-beta 1 receptor. In NRK 49F cells, the majority of bound TGF-beta 1 was cross-linked to a high molecular weight complex which probably represented the type III TGF-beta 1 receptor. NRK 49F cells also had type I TGF-beta 1 receptors and platelet factor 4 inhibited binding to these receptors in the NRK cells. Since the type I receptor contributed only a small percentage of total TGF-beta 1 binding, however, the overall effects of platelet factor 4 on TGF-beta 1 binding to NRK 49F cells were negligible. We were unable to demonstrate specific or saturable binding of platelet factor 4 to Hep 3B cells using either direct binding or affinity cross-linking assays. Thus, it is not clear whether platelet factor 4 inhibits TGF-beta 1 binding by competition for binding to the type I receptor. Modest concentrations of TGF-beta 1 reduced the adherence of Hep 3B cells to tissue culture dishes.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1658013     DOI: 10.1002/jcb.240470105

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  6 in total

1.  Platelet factor 4 limits Th17 differentiation and cardiac allograft rejection.

Authors:  Guanfang Shi; David J Field; Kyung-ae Ko; Sara Ture; Kalyan Srivastava; Scott Levy; M Anna Kowalska; Mortimer Poncz; Deborah J Fowell; Craig N Morrell
Journal:  J Clin Invest       Date:  2014-01-27       Impact factor: 14.808

2.  Platelet factor 4 binds to interleukin 8 receptors and activates neutrophils when its N terminus is modified with Glu-Leu-Arg.

Authors:  I Clark-Lewis; B Dewald; T Geiser; B Moser; M Baggiolini
Journal:  Proc Natl Acad Sci U S A       Date:  1993-04-15       Impact factor: 11.205

3.  Gene expression analysis of human otosclerotic stapedial footplates.

Authors:  Megan Ealy; Wenjie Chen; Gi-Yung Ryu; Jae-Geun Yoon; D Bradley Welling; Marlan Hansen; Anup Madan; Richard J H Smith
Journal:  Hear Res       Date:  2008-03-15       Impact factor: 3.208

Review 4.  Chemokines as molecular targets for therapeutic intervention.

Authors:  O M Howard; J J Oppenheim; J M Wang
Journal:  J Clin Immunol       Date:  1999-09       Impact factor: 8.317

5.  The IP-10 chemokine binds to a specific cell surface heparan sulfate site shared with platelet factor 4 and inhibits endothelial cell proliferation.

Authors:  A D Luster; S M Greenberg; P Leder
Journal:  J Exp Med       Date:  1995-07-01       Impact factor: 14.307

6.  Carboxyl-terminal heparin-binding fragments of platelet factor 4 retain the blocking effect on the receptor binding of basic fibroblast growth factor.

Authors:  Y Sato; M Waki; M Ohno; M Kuwano; T Sakata
Journal:  Jpn J Cancer Res       Date:  1993-05
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.